[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fnPH46_v6CgF0uj-KDcj5b3BMrqfqkOHdMZBBiHqzU-c":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":42,"rows":49},"Germans Trias i Pujol Hospital",[4],84,false,9,16496,2,35,[13,16,19,21,23,25,27,29],{"name":14,"count":15},"HIV Infections",25,{"name":17,"count":18},"HIV",6,{"name":20,"count":10},"Multiple Sclerosis",{"name":22,"count":10},"Major Depressive Disorder",{"name":24,"count":10},"Cholangiocarcinoma",{"name":26,"count":10},"Choledocholithiasis",{"name":28,"count":10},"Heart Failure",{"name":30,"count":10},"Tuberculosis",[32,37],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06514365","Comparison of the Analgesic Effect of Subsartorial Saphenous Block and Popliteal Sciatic vs Subsartorial Saphenous Block and IPACK in Total Knee Replacement Surgery.","2024-06-01","IPACK block with Bupivacaine 0.25% with adrenaline",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06337539","Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants","2026-12-31","SSRI",[43,44,45,46,47,48],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[50,78,103,157,201,232,254,281,303,321,347,365,383,409,427,454,472,490,515,533,557,581,605,630,648,669,691,709,733,751,775,797,822,845,868,891,915,933,951,975,1003,1027,1045,1074,1099,1117,1140,1164,1182,1206,1224,1248,1272,1298,1322,1347,1370,1388,1406,1424,1442,1460,1478,1506,1524,1551,1569,1587,1609,1635,1659,1683],{"intervention":41,"totalTrials":51,"cells":52},1,{"EARLY_PHASE1":53,"PHASE1":56,"PHASE2":58,"PHASE3":60,"PHASE4":62,"NA":64},{"trials":54,"activeCount":55},[],0,{"trials":57,"activeCount":55},[],{"trials":59,"activeCount":55},[],{"trials":61,"activeCount":55},[],{"trials":63,"activeCount":55},[],{"trials":65,"activeCount":51,"soonestReadout":40},[66],{"nctId":38,"briefTitle":39,"status":67,"phases":68,"primaryCompletion":40,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":77},"NOT_YET_RECRUITING",[],"2027-07-31","2024-04-01",50,[73,74,75,76],"Depression","Inflammation","Antidepressants","Immunity",[41],{"intervention":36,"totalTrials":51,"cells":79},{"EARLY_PHASE1":80,"PHASE1":82,"PHASE2":84,"PHASE3":86,"PHASE4":88,"NA":90},{"trials":81,"activeCount":55},[],{"trials":83,"activeCount":55},[],{"trials":85,"activeCount":55},[],{"trials":87,"activeCount":55},[],{"trials":89,"activeCount":55},[],{"trials":91,"activeCount":51,"soonestReadout":35},[92],{"nctId":33,"briefTitle":34,"status":93,"phases":94,"primaryCompletion":35,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":102},"RECRUITING",[48],"2024-08-01","2020-06-10",62,[99,100,101],"Pain, Acute","Knee Osteoarthritis","Anesthesia",[36],{"intervention":104,"totalTrials":105,"cells":106},"Nevirapine",3,{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":131,"PHASE3":133,"PHASE4":135,"NA":155},{"trials":108,"activeCount":55},[],{"trials":110,"activeCount":55},[111],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":120},"NCT00307502","Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","COMPLETED",[44],"2009-12","2005-01",675,[14],[104,121,122,123,124,125,126,127,128,129,130],"Efavirenz","Indinavir\u002Fritonavir","Nelfinavir","Saquinavir\u002Fritonavir","Lopinavir\u002Fritonavir","Atazanavir","Atazanavir\u002Fritonavir","Fos-amprenavir\u002Fritonavir","Tipranavir\u002F ritonavir","Darunavir\u002Fritonavir",{"trials":132,"activeCount":55},[],{"trials":134,"activeCount":55},[],{"trials":136,"activeCount":55},[137,147],{"nctId":138,"briefTitle":139,"status":114,"phases":140,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":145},"NCT00355719","Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients",[47],"2008-02","2007-01",14,[14],[126,146,104],"Ritonavir",{"nctId":148,"briefTitle":149,"status":150,"phases":151,"primaryCompletion":152,"completion":152,"start":141,"enrollment":8,"conditions":153,"interventions":154},"NCT00661349","Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV\u002FHCV Patients","TERMINATED",[47],"2008-12",[14],[125,104],{"trials":156,"activeCount":55},[],{"intervention":158,"totalTrials":105,"cells":159},"Raltegravir",{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":179,"NA":199},{"trials":161,"activeCount":55},[],{"trials":163,"activeCount":55},[],{"trials":165,"activeCount":55},[],{"trials":167,"activeCount":55},[168],{"nctId":169,"briefTitle":170,"status":114,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":176},"NCT00808002","Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir\u002FEmtricitabine",[46],"2011-11","2009-02",30,[14],[158,177,178],"Maraviroc","Tenofovir\u002FEmtricitabine",{"trials":180,"activeCount":55},[181,189],{"nctId":182,"briefTitle":183,"status":114,"phases":184,"primaryCompletion":116,"completion":116,"start":185,"enrollment":186,"conditions":187,"interventions":188},"NCT00995241","Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV",[47],"2009-11",5,[14],[158],{"nctId":190,"briefTitle":191,"status":114,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},"NCT00773708","Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product",[47],"2011-05","2009-03",57,[14],[198],"raltegravir",{"trials":200,"activeCount":55},[],{"intervention":125,"totalTrials":105,"cells":202},{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":230},{"trials":204,"activeCount":55},[],{"trials":206,"activeCount":55},[207],{"nctId":112,"briefTitle":113,"status":114,"phases":208,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":209,"interventions":210},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":212,"activeCount":55},[],{"trials":214,"activeCount":55},[],{"trials":216,"activeCount":55},[217,226],{"nctId":218,"briefTitle":219,"status":114,"phases":220,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":225},"NCT00994344","Clinical Study to Evaluate the Efficacy and Safety of Lopinavir\u002FRitonavir Monotherapy Versus Darunavir\u002FRitonavir Monotherapies as Simplification Switching Strategies of PI\u002FNNRTI-Triple Therapy Based-Regimens",[47],"2012-10","2009-10",73,[14],[130,125],{"nctId":148,"briefTitle":149,"status":150,"phases":227,"primaryCompletion":152,"completion":152,"start":141,"enrollment":8,"conditions":228,"interventions":229},[47],[14],[125,104],{"trials":231,"activeCount":55},[],{"intervention":126,"totalTrials":10,"cells":233},{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":252},{"trials":235,"activeCount":55},[],{"trials":237,"activeCount":55},[238],{"nctId":112,"briefTitle":113,"status":114,"phases":239,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":240,"interventions":241},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":243,"activeCount":55},[],{"trials":245,"activeCount":55},[],{"trials":247,"activeCount":55},[248],{"nctId":138,"briefTitle":139,"status":114,"phases":249,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":250,"interventions":251},[47],[14],[126,146,104],{"trials":253,"activeCount":55},[],{"intervention":177,"totalTrials":10,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":268,"NA":279},{"trials":257,"activeCount":55},[],{"trials":259,"activeCount":55},[],{"trials":261,"activeCount":55},[],{"trials":263,"activeCount":55},[264],{"nctId":169,"briefTitle":170,"status":114,"phases":265,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":266,"interventions":267},[46],[14],[158,177,178],{"trials":269,"activeCount":55},[270],{"nctId":271,"briefTitle":272,"status":114,"phases":273,"primaryCompletion":274,"completion":274,"start":222,"enrollment":174,"conditions":275,"interventions":276},"NCT00966329","Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects",[47],"2012-05",[17,14],[277,278],"maraviroc","control group",{"trials":280,"activeCount":55},[],{"intervention":130,"totalTrials":10,"cells":282},{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":301},{"trials":284,"activeCount":55},[],{"trials":286,"activeCount":55},[287],{"nctId":112,"briefTitle":113,"status":114,"phases":288,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":289,"interventions":290},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":292,"activeCount":55},[],{"trials":294,"activeCount":55},[],{"trials":296,"activeCount":55},[297],{"nctId":218,"briefTitle":219,"status":114,"phases":298,"primaryCompletion":221,"completion":221,"start":222,"enrollment":223,"conditions":299,"interventions":300},[47],[14],[130,125],{"trials":302,"activeCount":55},[],{"intervention":146,"totalTrials":51,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":319},{"trials":306,"activeCount":55},[],{"trials":308,"activeCount":55},[],{"trials":310,"activeCount":55},[],{"trials":312,"activeCount":55},[],{"trials":314,"activeCount":55},[315],{"nctId":138,"briefTitle":139,"status":114,"phases":316,"primaryCompletion":141,"completion":141,"start":142,"enrollment":143,"conditions":317,"interventions":318},[47],[14],[126,146,104],{"trials":320,"activeCount":55},[],{"intervention":322,"totalTrials":51,"cells":323},"recombinant human Growth Hormone",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":345},{"trials":325,"activeCount":55},[],{"trials":327,"activeCount":55},[],{"trials":329,"activeCount":55},[],{"trials":331,"activeCount":55},[],{"trials":333,"activeCount":55},[334],{"nctId":335,"briefTitle":336,"status":114,"phases":337,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":342},"NCT00287677","Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients",[47],"2009-07","2006-01",33,[14],[322,343,344],"Vaccination","HAART",{"trials":346,"activeCount":55},[],{"intervention":343,"totalTrials":51,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":363},{"trials":350,"activeCount":55},[],{"trials":352,"activeCount":55},[],{"trials":354,"activeCount":55},[],{"trials":356,"activeCount":55},[],{"trials":358,"activeCount":55},[359],{"nctId":335,"briefTitle":336,"status":114,"phases":360,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":361,"interventions":362},[47],[14],[322,343,344],{"trials":364,"activeCount":55},[],{"intervention":344,"totalTrials":51,"cells":366},{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":381},{"trials":368,"activeCount":55},[],{"trials":370,"activeCount":55},[],{"trials":372,"activeCount":55},[],{"trials":374,"activeCount":55},[],{"trials":376,"activeCount":55},[377],{"nctId":335,"briefTitle":336,"status":114,"phases":378,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":379,"interventions":380},[47],[14],[322,343,344],{"trials":382,"activeCount":55},[],{"intervention":384,"totalTrials":51,"cells":385},"Methylprednisolone 1250 mg\u002F24h x3 days",{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":392,"PHASE4":394,"NA":407},{"trials":387,"activeCount":55},[],{"trials":389,"activeCount":55},[],{"trials":391,"activeCount":55},[],{"trials":393,"activeCount":55},[],{"trials":395,"activeCount":55},[396],{"nctId":397,"briefTitle":398,"status":114,"phases":399,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":405},"NCT01986998","Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse",[47],"2016-02","2016-03","2013-10",49,[20],[384,406],"Oral Methylprednisolone 625 mg\u002F24h x3 days",{"trials":408,"activeCount":55},[],{"intervention":406,"totalTrials":51,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":419,"NA":425},{"trials":412,"activeCount":55},[],{"trials":414,"activeCount":55},[],{"trials":416,"activeCount":55},[],{"trials":418,"activeCount":55},[],{"trials":420,"activeCount":55},[421],{"nctId":397,"briefTitle":398,"status":114,"phases":422,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":423,"interventions":424},[47],[20],[384,406],{"trials":426,"activeCount":55},[],{"intervention":428,"totalTrials":51,"cells":429},"Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug\u002Fweek",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":452},{"trials":431,"activeCount":55},[],{"trials":433,"activeCount":55},[],{"trials":435,"activeCount":55},[],{"trials":437,"activeCount":55},[],{"trials":439,"activeCount":55},[440],{"nctId":441,"briefTitle":442,"status":114,"phases":443,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":449},"NCT00470210","Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV\u002FHIV Not Responding to Previous Treatment Regimens",[47],"2009-06","2007-05",10,[448,14],"Hepatitis C",[428,450,451],"Ribavirin (Copegus®) 1600 mg\u002Fday","Epoetin β",{"trials":453,"activeCount":55},[],{"intervention":450,"totalTrials":51,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":464,"NA":470},{"trials":457,"activeCount":55},[],{"trials":459,"activeCount":55},[],{"trials":461,"activeCount":55},[],{"trials":463,"activeCount":55},[],{"trials":465,"activeCount":55},[466],{"nctId":441,"briefTitle":442,"status":114,"phases":467,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":468,"interventions":469},[47],[448,14],[428,450,451],{"trials":471,"activeCount":55},[],{"intervention":451,"totalTrials":51,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":488},{"trials":475,"activeCount":55},[],{"trials":477,"activeCount":55},[],{"trials":479,"activeCount":55},[],{"trials":481,"activeCount":55},[],{"trials":483,"activeCount":55},[484],{"nctId":441,"briefTitle":442,"status":114,"phases":485,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":486,"interventions":487},[47],[448,14],[428,450,451],{"trials":489,"activeCount":55},[],{"intervention":491,"totalTrials":51,"cells":492},"Lopinavir-rtv (Kaletra): 3 capsules (600 mg)\u002F12 h",{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":513},{"trials":494,"activeCount":55},[],{"trials":496,"activeCount":55},[],{"trials":498,"activeCount":55},[],{"trials":500,"activeCount":55},[],{"trials":502,"activeCount":55},[503],{"nctId":504,"briefTitle":505,"status":114,"phases":506,"primaryCompletion":507,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":511},"NCT00335686","Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients",[47],"2006-03","2003-10",67,[14],[491,512],"Nevirapine (Viramune): 1 comp (200mg)\u002F12h",{"trials":514,"activeCount":55},[],{"intervention":512,"totalTrials":51,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":531},{"trials":518,"activeCount":55},[],{"trials":520,"activeCount":55},[],{"trials":522,"activeCount":55},[],{"trials":524,"activeCount":55},[],{"trials":526,"activeCount":55},[527],{"nctId":504,"briefTitle":505,"status":114,"phases":528,"primaryCompletion":507,"completion":507,"start":508,"enrollment":509,"conditions":529,"interventions":530},[47],[14],[491,512],{"trials":532,"activeCount":55},[],{"intervention":534,"totalTrials":51,"cells":535},"Efavirenz capsules 200 mg and 600 mg",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":555},{"trials":537,"activeCount":55},[],{"trials":539,"activeCount":55},[],{"trials":541,"activeCount":55},[],{"trials":543,"activeCount":55},[],{"trials":545,"activeCount":55},[546],{"nctId":547,"briefTitle":548,"status":114,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":554},"NCT00299091","Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients",[47],"2008-10","2006-09",31,[17],[534],{"trials":556,"activeCount":55},[],{"intervention":558,"totalTrials":51,"cells":559},"Saquinavir\u002FRitonavir : 2 capsules (500 mg) \u002F 12 hours",{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":579},{"trials":561,"activeCount":55},[],{"trials":563,"activeCount":55},[],{"trials":565,"activeCount":55},[],{"trials":567,"activeCount":55},[],{"trials":569,"activeCount":55},[570],{"nctId":571,"briefTitle":572,"status":114,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":174,"conditions":577,"interventions":578},"NCT00379405","Saquinavir\u002FRitonavir in Single Therapy as Maintenance Treatment",[47],"2008-05","2008-07","2006-06",[14],[558],{"trials":580,"activeCount":55},[],{"intervention":582,"totalTrials":51,"cells":583},"Atorvastatin 40 mg\u002FAtorvastatin 80 mg",{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":592,"NA":603},{"trials":585,"activeCount":55},[],{"trials":587,"activeCount":55},[],{"trials":589,"activeCount":55},[],{"trials":591,"activeCount":55},[],{"trials":593,"activeCount":55},[594],{"nctId":595,"briefTitle":596,"status":150,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":186,"conditions":601,"interventions":602},"NCT00355251","Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption",[47],"2006-12","2007-02","2006-07",[14],[582],{"trials":604,"activeCount":55},[],{"intervention":606,"totalTrials":51,"cells":607},"Trizivir (AZT+3HT+Abacavir) twice daily",{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":616,"NA":628},{"trials":609,"activeCount":55},[],{"trials":611,"activeCount":55},[],{"trials":613,"activeCount":55},[],{"trials":615,"activeCount":55},[],{"trials":617,"activeCount":55},[618],{"nctId":619,"briefTitle":620,"status":150,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":626},"NCT00356616","Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients",[47],"2007-06","2005-09",24,[14],[606,627],"Viread (300 mg Tenofovir disoproxil fumarate) once daily",{"trials":629,"activeCount":55},[],{"intervention":627,"totalTrials":51,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":640,"NA":646},{"trials":633,"activeCount":55},[],{"trials":635,"activeCount":55},[],{"trials":637,"activeCount":55},[],{"trials":639,"activeCount":55},[],{"trials":641,"activeCount":55},[642],{"nctId":619,"briefTitle":620,"status":150,"phases":643,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":644,"interventions":645},[47],[14],[606,627],{"trials":647,"activeCount":55},[],{"intervention":649,"totalTrials":51,"cells":650},"Zoledronic acid",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":659,"NA":667},{"trials":652,"activeCount":55},[],{"trials":654,"activeCount":55},[],{"trials":656,"activeCount":55},[],{"trials":658,"activeCount":55},[],{"trials":660,"activeCount":55},[661],{"nctId":662,"briefTitle":663,"status":114,"phases":664,"primaryCompletion":172,"completion":172,"start":185,"enrollment":340,"conditions":665,"interventions":666},"NCT00795483","Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' Cohort",[47],[14],[649,649],{"trials":668,"activeCount":55},[],{"intervention":670,"totalTrials":51,"cells":671},"Darunavir 900mg + ritonavir 100 mg once a day",{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":678,"PHASE4":680,"NA":689},{"trials":673,"activeCount":55},[],{"trials":675,"activeCount":55},[],{"trials":677,"activeCount":55},[],{"trials":679,"activeCount":55},[],{"trials":681,"activeCount":55},[682],{"nctId":683,"briefTitle":684,"status":114,"phases":685,"primaryCompletion":338,"completion":338,"start":141,"enrollment":174,"conditions":686,"interventions":687},"NCT00611039","Evaluate the Efficacy and Security of Darunavir\u002FRitonavir 900\u002F100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy",[47],[14],[670,688],"Darunavir 600mg + ritonavir 100mg twice day",{"trials":690,"activeCount":55},[],{"intervention":688,"totalTrials":51,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":707},{"trials":694,"activeCount":55},[],{"trials":696,"activeCount":55},[],{"trials":698,"activeCount":55},[],{"trials":700,"activeCount":55},[],{"trials":702,"activeCount":55},[703],{"nctId":683,"briefTitle":684,"status":114,"phases":704,"primaryCompletion":338,"completion":338,"start":141,"enrollment":174,"conditions":705,"interventions":706},[47],[14],[670,688],{"trials":708,"activeCount":55},[],{"intervention":710,"totalTrials":51,"cells":711},"Peginterferon alfa-2a, Ribavirin, epoetin-β",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":731},{"trials":713,"activeCount":55},[],{"trials":715,"activeCount":55},[],{"trials":717,"activeCount":55},[],{"trials":719,"activeCount":55},[],{"trials":721,"activeCount":55},[722],{"nctId":723,"briefTitle":724,"status":114,"phases":725,"primaryCompletion":194,"completion":194,"start":726,"enrollment":727,"conditions":728,"interventions":729},"NCT00356486","Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV\u002FHIV",[47],"2005-10",74,[14],[710,730],"Peginterferon alfa-2a + Ribavirin for 12 weeks",{"trials":732,"activeCount":55},[],{"intervention":730,"totalTrials":51,"cells":734},{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":741,"PHASE4":743,"NA":749},{"trials":736,"activeCount":55},[],{"trials":738,"activeCount":55},[],{"trials":740,"activeCount":55},[],{"trials":742,"activeCount":55},[],{"trials":744,"activeCount":55},[745],{"nctId":723,"briefTitle":724,"status":114,"phases":746,"primaryCompletion":194,"completion":194,"start":726,"enrollment":727,"conditions":747,"interventions":748},[47],[14],[710,730],{"trials":750,"activeCount":55},[],{"intervention":752,"totalTrials":51,"cells":753},"Vitamin D",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":773},{"trials":755,"activeCount":55},[],{"trials":757,"activeCount":55},[],{"trials":759,"activeCount":55},[],{"trials":761,"activeCount":55},[],{"trials":763,"activeCount":55},[764],{"nctId":765,"briefTitle":766,"status":114,"phases":767,"primaryCompletion":768,"completion":768,"start":769,"enrollment":10,"conditions":770,"interventions":772},"NCT04197089","Biological Effect of Vitamin D in Patients With Urothelial Carcinoma",[47],"2021-11-22","2020-02-11",[771],"Urothelial Carcinoma",[752],{"trials":774,"activeCount":55},[],{"intervention":776,"totalTrials":51,"cells":777},"Ibandronate",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":795},{"trials":779,"activeCount":55},[],{"trials":781,"activeCount":55},[],{"trials":783,"activeCount":55},[],{"trials":785,"activeCount":55},[],{"trials":787,"activeCount":55},[788],{"nctId":789,"briefTitle":790,"status":791,"phases":792,"enrollment":55,"conditions":793,"interventions":794},"NCT00662077","Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort","WITHDRAWN",[47],[14],[776],{"trials":796,"activeCount":55},[],{"intervention":798,"totalTrials":51,"cells":799},"Echinacea",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":820},{"trials":801,"activeCount":55},[],{"trials":803,"activeCount":55},[],{"trials":805,"activeCount":55},[],{"trials":807,"activeCount":55},[],{"trials":809,"activeCount":55},[810],{"nctId":811,"briefTitle":812,"status":114,"phases":813,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":819},"NCT01046890","Drug Interactions Between Echinacea Purpurea and Darunavir\u002FRitonavir",[47],"2010-03","2010-04","2010-01",15,[14],[798],{"trials":821,"activeCount":55},[],{"intervention":823,"totalTrials":51,"cells":824},"Lumbar puncture",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":843},{"trials":826,"activeCount":55},[],{"trials":828,"activeCount":55},[],{"trials":830,"activeCount":55},[],{"trials":832,"activeCount":55},[],{"trials":834,"activeCount":55},[835],{"nctId":836,"briefTitle":837,"status":114,"phases":838,"primaryCompletion":839,"completion":839,"start":840,"enrollment":11,"conditions":841,"interventions":842},"NCT01116817","Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir \u002F Ritonavir Monotherapy",[47],"2011-06","2010-08",[17],[823,823],{"trials":844,"activeCount":55},[],{"intervention":846,"totalTrials":51,"cells":847},"Salvage antiretroviral therapy including raltegravir",{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":866},{"trials":849,"activeCount":55},[],{"trials":851,"activeCount":55},[],{"trials":853,"activeCount":55},[],{"trials":855,"activeCount":55},[],{"trials":857,"activeCount":55},[858],{"nctId":859,"briefTitle":860,"status":114,"phases":861,"primaryCompletion":862,"completion":222,"start":863,"enrollment":817,"conditions":864,"interventions":865},"NCT00685191","HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain",[47],"2009-04","2008-06",[14],[846],{"trials":867,"activeCount":55},[],{"intervention":869,"totalTrials":51,"cells":870},"Addition of raltegravir 800 mg QD to HAART",{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":879,"NA":889},{"trials":872,"activeCount":55},[],{"trials":874,"activeCount":55},[],{"trials":876,"activeCount":55},[],{"trials":878,"activeCount":55},[],{"trials":880,"activeCount":55},[881],{"nctId":882,"briefTitle":883,"status":114,"phases":884,"primaryCompletion":885,"completion":885,"start":886,"enrollment":817,"conditions":887,"interventions":888},"NCT00718536","Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy",[47],"2009-01","2008-08",[14],[869],{"trials":890,"activeCount":55},[],{"intervention":892,"totalTrials":51,"cells":893},"Patients in treatment with 3TC + TDF + LPV\u002Frtv, stop tenofovir during 4 weeks",{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":900,"PHASE4":902,"NA":913},{"trials":895,"activeCount":55},[],{"trials":897,"activeCount":55},[],{"trials":899,"activeCount":55},[],{"trials":901,"activeCount":55},[],{"trials":903,"activeCount":55},[904],{"nctId":905,"briefTitle":906,"status":114,"phases":907,"primaryCompletion":623,"completion":623,"start":117,"enrollment":908,"conditions":909,"interventions":910},"NCT00335192","To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir",[47],32,[17],[892,911,912],"Patients in treatment with ABV + TDF + LPV\u002Frtv, stop tenofovir during 4 weeks","Patients in treatment with 3TC + ABV + TDF+ LPV\u002Frtv, stop TDF during 4 weeks",{"trials":914,"activeCount":55},[],{"intervention":911,"totalTrials":51,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":923,"PHASE4":925,"NA":931},{"trials":918,"activeCount":55},[],{"trials":920,"activeCount":55},[],{"trials":922,"activeCount":55},[],{"trials":924,"activeCount":55},[],{"trials":926,"activeCount":55},[927],{"nctId":905,"briefTitle":906,"status":114,"phases":928,"primaryCompletion":623,"completion":623,"start":117,"enrollment":908,"conditions":929,"interventions":930},[47],[17],[892,911,912],{"trials":932,"activeCount":55},[],{"intervention":912,"totalTrials":51,"cells":934},{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":943,"NA":949},{"trials":936,"activeCount":55},[],{"trials":938,"activeCount":55},[],{"trials":940,"activeCount":55},[],{"trials":942,"activeCount":55},[],{"trials":944,"activeCount":55},[945],{"nctId":905,"briefTitle":906,"status":114,"phases":946,"primaryCompletion":623,"completion":623,"start":117,"enrollment":908,"conditions":947,"interventions":948},[47],[17],[892,911,912],{"trials":950,"activeCount":55},[],{"intervention":952,"totalTrials":51,"cells":953},"methylprednisolone",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":973},{"trials":955,"activeCount":55},[],{"trials":957,"activeCount":55},[],{"trials":959,"activeCount":55},[],{"trials":961,"activeCount":55},[],{"trials":963,"activeCount":55},[964],{"nctId":965,"briefTitle":966,"status":114,"phases":967,"primaryCompletion":968,"completion":969,"start":970,"enrollment":403,"conditions":971,"interventions":972},"NCT00753792","Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse",[47],"2010-11","2011-01","2008-11",[20],[952,952],{"trials":974,"activeCount":55},[],{"intervention":976,"totalTrials":51,"cells":977},"Tisseel",{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":1001},{"trials":979,"activeCount":55},[],{"trials":981,"activeCount":55},[],{"trials":983,"activeCount":55},[],{"trials":985,"activeCount":55},[],{"trials":987,"activeCount":55},[988],{"nctId":989,"briefTitle":990,"status":991,"phases":992,"primaryCompletion":993,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":1000},"NCT03733639","Tisseel® as a Reinforcement of Esophagojejunal Anastomoses","UNKNOWN",[47],"2021-07-01","2022-07-01","2020-07-21",146,[998,999],"Gastric Cancer","Anastomotic Leak",[976],{"trials":1002,"activeCount":55},[],{"intervention":1004,"totalTrials":51,"cells":1005},"tipranavir\u002Fritonavir",{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1014,"NA":1025},{"trials":1007,"activeCount":55},[],{"trials":1009,"activeCount":55},[],{"trials":1011,"activeCount":55},[],{"trials":1013,"activeCount":55},[],{"trials":1015,"activeCount":55},[1016],{"nctId":1017,"briefTitle":1018,"status":114,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1024},"NCT00607958","Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir\u002FRitonavir 500\u002F200 mg Every 12 Hours",[47],"2009-05","2007-12",11,[14],[1004],{"trials":1026,"activeCount":55},[],{"intervention":278,"totalTrials":51,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1043},{"trials":1030,"activeCount":55},[],{"trials":1032,"activeCount":55},[],{"trials":1034,"activeCount":55},[],{"trials":1036,"activeCount":55},[],{"trials":1038,"activeCount":55},[1039],{"nctId":271,"briefTitle":272,"status":114,"phases":1040,"primaryCompletion":274,"completion":274,"start":222,"enrollment":174,"conditions":1041,"interventions":1042},[47],[17,14],[277,278],{"trials":1044,"activeCount":55},[],{"intervention":1046,"totalTrials":10,"cells":1047},"efavirenz",{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1056,"PHASE3":1058,"PHASE4":1070,"NA":1072},{"trials":1049,"activeCount":55},[],{"trials":1051,"activeCount":55},[1052],{"nctId":112,"briefTitle":113,"status":114,"phases":1053,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":1054,"interventions":1055},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":1057,"activeCount":55},[],{"trials":1059,"activeCount":55},[1060],{"nctId":1061,"briefTitle":1062,"status":114,"phases":1063,"primaryCompletion":599,"completion":1064,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1068},"NCT00314626","Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily",[46],"2007-03","2004-11",99,[14],[1046,1069],"Abacavir+lamivudine",{"trials":1071,"activeCount":55},[],{"trials":1073,"activeCount":55},[],{"intervention":1075,"totalTrials":51,"cells":1076},"Sacubitril \u002F Valsartan Oral Tablet [Entresto]",{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1083,"PHASE4":1095,"NA":1097},{"trials":1078,"activeCount":55},[],{"trials":1080,"activeCount":55},[],{"trials":1082,"activeCount":55},[],{"trials":1084,"activeCount":55},[1085],{"nctId":1086,"briefTitle":1087,"status":114,"phases":1088,"primaryCompletion":1089,"completion":1090,"start":1091,"enrollment":143,"conditions":1092,"interventions":1094},"NCT04753112","Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device",[46],"2021-09-08","2021-09-20","2020-10-29",[1093],"Pulmonary Hypertension",[1075],{"trials":1096,"activeCount":55},[],{"trials":1098,"activeCount":55},[],{"intervention":178,"totalTrials":51,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1113,"NA":1115},{"trials":1102,"activeCount":55},[],{"trials":1104,"activeCount":55},[],{"trials":1106,"activeCount":55},[],{"trials":1108,"activeCount":55},[1109],{"nctId":169,"briefTitle":170,"status":114,"phases":1110,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":1111,"interventions":1112},[46],[14],[158,177,178],{"trials":1114,"activeCount":55},[],{"trials":1116,"activeCount":55},[],{"intervention":1118,"totalTrials":51,"cells":1119},"Duloxetine 60 mg, QD",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1136,"NA":1138},{"trials":1121,"activeCount":55},[],{"trials":1123,"activeCount":55},[],{"trials":1125,"activeCount":55},[],{"trials":1127,"activeCount":55},[1128],{"nctId":1129,"briefTitle":1130,"status":114,"phases":1131,"primaryCompletion":338,"completion":338,"start":142,"enrollment":446,"conditions":1132,"interventions":1135},"NCT00552682","Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+",[46],[1133,1134],"Fibromyalgia","HIV-1 Infection",[1118],{"trials":1137,"activeCount":55},[],{"trials":1139,"activeCount":55},[],{"intervention":1141,"totalTrials":51,"cells":1142},"Etravirine 400 mg dissolved in water every 24 hours",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1160,"NA":1162},{"trials":1144,"activeCount":55},[],{"trials":1146,"activeCount":55},[],{"trials":1148,"activeCount":55},[],{"trials":1150,"activeCount":55},[1151],{"nctId":1152,"briefTitle":1153,"status":114,"phases":1154,"primaryCompletion":1155,"completion":1155,"start":116,"enrollment":1156,"conditions":1157,"interventions":1158},"NCT01034917","Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression",[46],"2011-12",43,[17],[1141,1159],"Continue with the same antiretroviral regimen",{"trials":1161,"activeCount":55},[],{"trials":1163,"activeCount":55},[],{"intervention":1159,"totalTrials":51,"cells":1165},{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1178,"NA":1180},{"trials":1167,"activeCount":55},[],{"trials":1169,"activeCount":55},[],{"trials":1171,"activeCount":55},[],{"trials":1173,"activeCount":55},[1174],{"nctId":1152,"briefTitle":1153,"status":114,"phases":1175,"primaryCompletion":1155,"completion":1155,"start":116,"enrollment":1156,"conditions":1176,"interventions":1177},[46],[17],[1141,1159],{"trials":1179,"activeCount":55},[],{"trials":1181,"activeCount":55},[],{"intervention":1183,"totalTrials":51,"cells":1184},"MK-0518 400mg twice a day",{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1202,"NA":1204},{"trials":1186,"activeCount":55},[],{"trials":1188,"activeCount":55},[],{"trials":1190,"activeCount":55},[],{"trials":1192,"activeCount":55},[1193],{"nctId":1194,"briefTitle":1195,"status":114,"phases":1196,"primaryCompletion":1020,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1201},"NCT00554398","Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression",[46],"2009-09","2007-11",69,[14],[1183],{"trials":1203,"activeCount":55},[],{"trials":1205,"activeCount":55},[],{"intervention":1069,"totalTrials":51,"cells":1207},{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1220,"NA":1222},{"trials":1209,"activeCount":55},[],{"trials":1211,"activeCount":55},[],{"trials":1213,"activeCount":55},[],{"trials":1215,"activeCount":55},[1216],{"nctId":1061,"briefTitle":1062,"status":114,"phases":1217,"primaryCompletion":599,"completion":1064,"start":1065,"enrollment":1066,"conditions":1218,"interventions":1219},[46],[14],[1046,1069],{"trials":1221,"activeCount":55},[],{"trials":1223,"activeCount":55},[],{"intervention":1225,"totalTrials":51,"cells":1226},"Switch from tenofovir to abacavir",{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1244,"NA":1246},{"trials":1228,"activeCount":55},[],{"trials":1230,"activeCount":55},[],{"trials":1232,"activeCount":55},[],{"trials":1234,"activeCount":55},[1235],{"nctId":1236,"briefTitle":1237,"status":114,"phases":1238,"primaryCompletion":1239,"completion":1239,"start":1240,"enrollment":1241,"conditions":1242,"interventions":1243},"NCT01153217","Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density",[46],"2012-06","2010-07",54,[17],[1225],{"trials":1245,"activeCount":55},[],{"trials":1247,"activeCount":55},[],{"intervention":1249,"totalTrials":51,"cells":1250},"Kivexa",{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1257,"PHASE4":1268,"NA":1270},{"trials":1252,"activeCount":55},[],{"trials":1254,"activeCount":55},[],{"trials":1256,"activeCount":55},[],{"trials":1258,"activeCount":55},[1259],{"nctId":1260,"briefTitle":1261,"status":114,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1267},"NCT00318123","Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients",[46],"2007-04","2004-04",126,[14],[1249],{"trials":1269,"activeCount":55},[],{"trials":1271,"activeCount":55},[],{"intervention":1273,"totalTrials":51,"cells":1274},"Platelet-rich plasma",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1281,"PHASE4":1294,"NA":1296},{"trials":1276,"activeCount":55},[],{"trials":1278,"activeCount":55},[],{"trials":1280,"activeCount":55},[],{"trials":1282,"activeCount":55},[1283],{"nctId":1284,"briefTitle":1285,"status":114,"phases":1286,"primaryCompletion":1287,"completion":1287,"start":1288,"enrollment":1022,"conditions":1289,"interventions":1293},"NCT02931149","Evaluation of the Efficacy of Platelet-rich Plasma (PRP) on Advanced Endoscopic Resection Techniques",[46],"2017-02","2016-08",[1290,1291,1292],"Platelet-rich Plasma","Endoscopic Mucosal Resection","Endoscopic Submucosal Dissection",[1273],{"trials":1295,"activeCount":55},[],{"trials":1297,"activeCount":55},[],{"intervention":1299,"totalTrials":51,"cells":1300},"Bone marrow autologous mesenchymal stem cells transplantation",{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1316,"PHASE4":1318,"NA":1320},{"trials":1302,"activeCount":55},[],{"trials":1304,"activeCount":55},[],{"trials":1306,"activeCount":55},[1307],{"nctId":1308,"briefTitle":1309,"status":114,"phases":1310,"primaryCompletion":1311,"completion":1311,"start":1312,"enrollment":8,"conditions":1313,"interventions":1315},"NCT02035514","Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis",[44,45],"2016-07","2013-12",[1314],"Relapsing Remitting Multiple Sclerosis (RRMS)",[1299],{"trials":1317,"activeCount":55},[],{"trials":1319,"activeCount":55},[],{"trials":1321,"activeCount":55},[],{"intervention":1323,"totalTrials":51,"cells":1324},"Escitalopram",{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1341,"PHASE4":1343,"NA":1345},{"trials":1326,"activeCount":55},[],{"trials":1328,"activeCount":55},[],{"trials":1330,"activeCount":55},[1331],{"nctId":1332,"briefTitle":1333,"status":114,"phases":1334,"primaryCompletion":1335,"completion":1335,"start":1336,"enrollment":1337,"conditions":1338,"interventions":1340},"NCT00166296","Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients",[45],"2007-10","2005-03",133,[22,1339],"Hepatitis C, Chronic",[1323],{"trials":1342,"activeCount":55},[],{"trials":1344,"activeCount":55},[],{"trials":1346,"activeCount":55},[],{"intervention":1348,"totalTrials":51,"cells":1349},"Deferoxamine",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1351,"activeCount":55},[],{"trials":1353,"activeCount":55},[],{"trials":1355,"activeCount":55},[1356],{"nctId":1357,"briefTitle":1358,"status":114,"phases":1359,"primaryCompletion":1155,"completion":1155,"start":1360,"enrollment":97,"conditions":1361,"interventions":1363},"NCT00777140","Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion",[45],"2008-09",[1362],"Ischemic Stroke, Acute",[1348],{"trials":1365,"activeCount":55},[],{"trials":1367,"activeCount":55},[],{"trials":1369,"activeCount":55},[],{"intervention":122,"totalTrials":51,"cells":1371},{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1380,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1373,"activeCount":55},[],{"trials":1375,"activeCount":55},[1376],{"nctId":112,"briefTitle":113,"status":114,"phases":1377,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":1378,"interventions":1379},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":1381,"activeCount":55},[],{"trials":1383,"activeCount":55},[],{"trials":1385,"activeCount":55},[],{"trials":1387,"activeCount":55},[],{"intervention":123,"totalTrials":51,"cells":1389},{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1398,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1391,"activeCount":55},[],{"trials":1393,"activeCount":55},[1394],{"nctId":112,"briefTitle":113,"status":114,"phases":1395,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":1396,"interventions":1397},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":1399,"activeCount":55},[],{"trials":1401,"activeCount":55},[],{"trials":1403,"activeCount":55},[],{"trials":1405,"activeCount":55},[],{"intervention":124,"totalTrials":51,"cells":1407},{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1409,"activeCount":55},[],{"trials":1411,"activeCount":55},[1412],{"nctId":112,"briefTitle":113,"status":114,"phases":1413,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":1414,"interventions":1415},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":1417,"activeCount":55},[],{"trials":1419,"activeCount":55},[],{"trials":1421,"activeCount":55},[],{"trials":1423,"activeCount":55},[],{"intervention":127,"totalTrials":51,"cells":1425},{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1427,"activeCount":55},[],{"trials":1429,"activeCount":55},[1430],{"nctId":112,"briefTitle":113,"status":114,"phases":1431,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":1432,"interventions":1433},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":1435,"activeCount":55},[],{"trials":1437,"activeCount":55},[],{"trials":1439,"activeCount":55},[],{"trials":1441,"activeCount":55},[],{"intervention":128,"totalTrials":51,"cells":1443},{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1452,"PHASE3":1454,"PHASE4":1456,"NA":1458},{"trials":1445,"activeCount":55},[],{"trials":1447,"activeCount":55},[1448],{"nctId":112,"briefTitle":113,"status":114,"phases":1449,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":1450,"interventions":1451},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":1453,"activeCount":55},[],{"trials":1455,"activeCount":55},[],{"trials":1457,"activeCount":55},[],{"trials":1459,"activeCount":55},[],{"intervention":129,"totalTrials":51,"cells":1461},{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1470,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1463,"activeCount":55},[],{"trials":1465,"activeCount":55},[1466],{"nctId":112,"briefTitle":113,"status":114,"phases":1467,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":1468,"interventions":1469},[44],[14],[104,121,122,123,124,125,126,127,128,129,130],{"trials":1471,"activeCount":55},[],{"trials":1473,"activeCount":55},[],{"trials":1475,"activeCount":55},[],{"trials":1477,"activeCount":55},[],{"intervention":1479,"totalTrials":51,"cells":1480},"Methylone",{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1498,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1482,"activeCount":55},[],{"trials":1484,"activeCount":55},[1485],{"nctId":1486,"briefTitle":1487,"status":991,"phases":1488,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":1492,"conditions":1493,"interventions":1496},"NCT05488171","Abuse Potential and Human Pharmacology of Methylone",[44],"2022-07-31","2022-09-30","2021-12-01",17,[1494,1495],"Substance Use","Healthy Subjects",[1479,1497],"3,4-methylenedioxymethamphetamine",{"trials":1499,"activeCount":55},[],{"trials":1501,"activeCount":55},[],{"trials":1503,"activeCount":55},[],{"trials":1505,"activeCount":55},[],{"intervention":1497,"totalTrials":51,"cells":1507},{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1516,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1509,"activeCount":55},[],{"trials":1511,"activeCount":55},[1512],{"nctId":1486,"briefTitle":1487,"status":991,"phases":1513,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":1492,"conditions":1514,"interventions":1515},[44],[1494,1495],[1479,1497],{"trials":1517,"activeCount":55},[],{"trials":1519,"activeCount":55},[],{"trials":1521,"activeCount":55},[],{"trials":1523,"activeCount":55},[],{"intervention":1525,"totalTrials":51,"cells":1526},"Cannabis decoction",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1543,"PHASE3":1545,"PHASE4":1547,"NA":1549},{"trials":1528,"activeCount":55},[],{"trials":1530,"activeCount":55},[1531],{"nctId":1532,"briefTitle":1533,"status":114,"phases":1534,"primaryCompletion":1535,"completion":1536,"start":1537,"enrollment":1156,"conditions":1538,"interventions":1540},"NCT04841993","Pharmacokinetics and Pharmacological Effects of a Standardized Cannabis Preparation",[44],"2019-12-18","2021-02-28","2018-12-10",[1539,1495],"Cannabis Use",[1525,1541,1542],"Cannabis oil","Vaporized cannabis",{"trials":1544,"activeCount":55},[],{"trials":1546,"activeCount":55},[],{"trials":1548,"activeCount":55},[],{"trials":1550,"activeCount":55},[],{"intervention":1541,"totalTrials":51,"cells":1552},{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1561,"PHASE3":1563,"PHASE4":1565,"NA":1567},{"trials":1554,"activeCount":55},[],{"trials":1556,"activeCount":55},[1557],{"nctId":1532,"briefTitle":1533,"status":114,"phases":1558,"primaryCompletion":1535,"completion":1536,"start":1537,"enrollment":1156,"conditions":1559,"interventions":1560},[44],[1539,1495],[1525,1541,1542],{"trials":1562,"activeCount":55},[],{"trials":1564,"activeCount":55},[],{"trials":1566,"activeCount":55},[],{"trials":1568,"activeCount":55},[],{"intervention":1542,"totalTrials":51,"cells":1570},{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1579,"PHASE3":1581,"PHASE4":1583,"NA":1585},{"trials":1572,"activeCount":55},[],{"trials":1574,"activeCount":55},[1575],{"nctId":1532,"briefTitle":1533,"status":114,"phases":1576,"primaryCompletion":1535,"completion":1536,"start":1537,"enrollment":1156,"conditions":1577,"interventions":1578},[44],[1539,1495],[1525,1541,1542],{"trials":1580,"activeCount":55},[],{"trials":1582,"activeCount":55},[],{"trials":1584,"activeCount":55},[],{"trials":1586,"activeCount":55},[],{"intervention":1588,"totalTrials":51,"cells":1589},"RUTI",{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1601,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1591,"activeCount":55},[],{"trials":1593,"activeCount":55},[1594],{"nctId":1595,"briefTitle":1596,"status":114,"phases":1597,"primaryCompletion":863,"completion":863,"start":1263,"enrollment":624,"conditions":1598,"interventions":1600},"NCT00546273","Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers",[44],[1599,30],"Latent Tuberculosis Infection",[1588,1588,1588,1588],{"trials":1602,"activeCount":55},[],{"trials":1604,"activeCount":55},[],{"trials":1606,"activeCount":55},[],{"trials":1608,"activeCount":55},[],{"intervention":1610,"totalTrials":51,"cells":1611},"ANTIBIOTIC",{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1618,"PHASE4":1620,"NA":1622},{"trials":1613,"activeCount":55},[],{"trials":1615,"activeCount":55},[],{"trials":1617,"activeCount":55},[],{"trials":1619,"activeCount":55},[],{"trials":1621,"activeCount":55},[],{"trials":1623,"activeCount":55},[1624],{"nctId":1625,"briefTitle":1626,"status":991,"phases":1627,"primaryCompletion":1628,"completion":1629,"start":1628,"enrollment":1630,"conditions":1631,"interventions":1634},"NCT03643198","Oral Antibiotics for Anal Abscess",[48],"2022-03-01","2025-12-31",210,[1632,1633],"Anal Fistula","Anal Abscess",[1610],{"intervention":1636,"totalTrials":51,"cells":1637},"iSGTL2",{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1642,"PHASE3":1644,"PHASE4":1646,"NA":1648},{"trials":1639,"activeCount":55},[],{"trials":1641,"activeCount":55},[],{"trials":1643,"activeCount":55},[],{"trials":1645,"activeCount":55},[],{"trials":1647,"activeCount":55},[],{"trials":1649,"activeCount":55},[1650],{"nctId":1651,"briefTitle":1652,"status":114,"phases":1653,"primaryCompletion":1654,"completion":1654,"start":1655,"enrollment":1656,"conditions":1657,"interventions":1658},"NCT03741972","Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure",[],"2022-04-04","2018-12-21",100,[28],[1636],{"intervention":1660,"totalTrials":51,"cells":1661},"adverse drug reaction",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1663,"activeCount":55},[],{"trials":1665,"activeCount":55},[],{"trials":1667,"activeCount":55},[],{"trials":1669,"activeCount":55},[],{"trials":1671,"activeCount":55},[],{"trials":1673,"activeCount":55},[1674],{"nctId":1675,"briefTitle":1676,"status":114,"phases":1677,"primaryCompletion":1678,"completion":1311,"start":400,"enrollment":1679,"conditions":1680,"interventions":1682},"NCT02838212","Adverse Drug Reactions With Fatal Outcome",[],"2016-06",1135,[1681],"Adverse Drug Reaction",[1660],{"intervention":1684,"totalTrials":51,"cells":1685},"TachoSil",{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1687,"activeCount":55},[],{"trials":1689,"activeCount":55},[],{"trials":1691,"activeCount":55},[],{"trials":1693,"activeCount":55},[],{"trials":1695,"activeCount":55},[],{"trials":1697,"activeCount":55},[1698],{"nctId":1699,"briefTitle":1700,"status":114,"phases":1701,"primaryCompletion":1702,"completion":1702,"start":1703,"enrollment":1704,"conditions":1705,"interventions":1707},"NCT05717335","Observational Pilot Study With TachoSil as a Ventricular Sealant",[],"2023-02-03","2022-05-01",20,[1706],"Intraventricular Neoplasm",[1684]]